XML 41 R13.htm IDEA: XBRL DOCUMENT
v3.22.1

SHARE CAPITAL, WARRANTS AND OPTIONS | 12 Months Ended
--- | ---
Dec. 31, 2021
Share Capital Warrants And Options |
SHARE CAPITAL, WARRANTS AND OPTIONS | 8. SHARE CAPITAL, WARRANTS AND OPTIONS The authorized capital of the Company comprises an unlimited number of common shares without par value and 100,000,000 Series 1 convertible preferred shares without par value.
| a) | Common shares issued and outstanding
2021 During the year ended December 31, 2021, the Company issued 13,080,314 common shares on exercise of warrants and options and received $1,641,675 in proceeds from the exercise of 12,580,314 warrants and $112,000 from the exercise of 500,000 options. There were no warrants or options exercised during the year ended December 31, 2020. As at December 31, 2021, the Company has 131,204,627 common shares issued and outstanding, (December 31, 2020 – 109,833,648). On April 20, 2021 the Company closed a non-brokered private placement consisting of an aggregate of 8,290,665 units of the Company (the “Units”) at a price of $0.24 per unit, for aggregate gross proceeds of $1,989,760. Each unit consists of one common share in the capital of the Company and one half transferable common share purchase warrant (“Warrant”) of the Company. Each full Warrant entitles the holder to acquire one common share of the Company within twenty-four (24) months following its issuance date, at a price of $0.35. The warrants are subject to an acceleration clause such that if the closing market price of the common shares on the TSX-V is greater than $0.60 per common share for a period of 10 consecutive trading days at any time after the four-month anniversary of the closing of the placement, the Company may, at its option, accelerate the warrant expiry date to within 30 days. In connection with the private placement, the Company has paid eligible finders (the “Finders”): (i) cash commission equal to % of the gross proceeds raised from subscribers introduced to the Company by such Finders, being an aggregate of $65,830, and (ii) a number of common share purchase warrants (the “Finder Warrants”) equal to 6% of the units attributable to the Finders under the private placement, being an aggregate of 274,289 Finder Warrants. Each Finder Warrant entitles the Finder to acquire one common share of the Company for a period of twenty-four (24) months following its issuance date, at an exercise price of $0.35. The Company allocated a $464,493 fair value to the warrants issued in conjunction with the private placement and $30,735 to agent’s warrants. The fair value of warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions; expected life of 1.5 years, expected dividend yield of 0%, a risk-free interest rate of 0.29% and an expected volatility of 132%. 2020 On August 13, 2020, the Company closed the first tranche of its non-brokered private placement equity financing consisting of 15,481,077 units of the Company at a price of $0.07 per unit, for aggregate gross proceeds of $1,083,675. On August 31, 2020, the Company closed the second and final tranche of its non-brokered private placement equity financing consisting of 5,661,780 units of the Company at a price of $0.07 per unit, for aggregate gross proceeds of $396,325. Each unit consists of one common share in the capital of the Company and one transferable common share purchase warrant of the Company. Each warrant will entitle the holder to acquire one common share of the Company at an exercise price of $0.09 for a period of 24 months from its date of issuance. The warrants are subject to an acceleration clause such that if the closing market price of the common shares on the TSX-V is greater than $0.12 per common share for a period of 10 consecutive trading days at any time after the four-month anniversary of the closing of the placement, the Company may, at its option, accelerate the warrant expiry date to within 30 days. In connection with the non-brokered private financing, the Company incurred total share issuance costs of $124,222. The Company issued an aggregate of 588,154 common share purchase warrants. Each warrant will entitle the holder to acquire one common share of the Company at an exercise price of $0.09 for a period of 24 months from its date of issuance. The Company allocated a $716,055 fair value to the warrants issued in conjunction with the private placement and $18,547 to agent’s warrants. The fair value of warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions; expected life of 2 years, expected dividend yield of 0%, a risk-free interest rate of 0.28% to 0.31% range and an expected volatility of 158% to 158.53% range. 2019 On October 24, 2019 the TSXV approved the filing of the earn in agreement for the Loveland Nickel Property. As a result, on December 9, 2019, the Company issued 300,000 common shares at fair value of $51,000 (note 6). On December 18, 2019, the Company closed a non-brokered private placement equity financing of 7,373,265 units at a price of $0.18 and 2,224,666 flow-through common shares at a price of $0.18 and raised aggregate gross proceeds of $1,727,628. Each unit issued consisted of one common share in the capital of the Company and one-half of one common share purchase warrant. Each warrant will entitle the holder to acquire one common share of the Company at an exercise price of $0.25 for a period of 24 months from its date of issuance. All Securities issued pursuant to this offering were subject to a hold period which expired on April 19, 2020. The Company incurred total share issuance costs of $343,639. The Company allocated a $265,217 fair value to the warrants issued in conjunction with the private placement and $21,445 to 298,099 agent’s warrants. The fair value of warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions; expected life of 2 years, expected dividend yield of 0%, a risk-free interest rate of 1.73% and an expected volatility of 147.26%. On issuance, the Company bifurcated the flow-through shares into i) a flow-through share premium of $88,987 that investors paid for the flow-through feature, which is recognized as a liability and; ii) share capital of $311,453. To December 31, 2020, the Company expended $400,440 (December 31, 2019 – $Nil) in eligible exploration expenditures and, accordingly, the flow-through liability was reduced to $Nil. Notes to the Consolidated Financial Statements For the year ended December 31, 2021 (Expressed in Canadian dollars)
| b) | Preferred shares issued and outstanding
As at December 31, 2021, December 31, 2020 and December 31, 2019 there are 590,931 series 1 preferred shares outstanding. The rights and restrictions of the preferred shares are as follows:
| i) | dividends shall be paid at the discretion of the directors;
| ii) | the holders of the preferred shares are not entitled to vote except at meetings of the holders of the preferred shares, where they are entitled to one vote for each preferred share held;
| iii) | the shares are convertible at any time after 6 months from the date of issuance, upon the holder serving the Company with 10 days written notice; and
| iv) | the number of the common shares to be received on conversion of the preferred shares is to be determined by dividing the conversion value of the share, $1 per share, by $9.00.
| c) | Warrants
A summary of common share purchase warrants activity during the years ended December 31, 2021, December 31, 2020 and December 31, 2019 is as follows: SCHEDULE OF NUMBER AND WEIGHTED AVERAGE EXERCISE PRICES OF WARRANTS
|  | December 31, 2021 |  |  | December 31, 2020 |  |  | December 31, 2019 |
|  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |  |  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |  |  |  | Number Outstanding |  |  |  | Weighted Average Exercise Price ($) |
Outstanding, beginning of year |  |  | 25,715,742 |  |  |  | 0.11 |  |  |  | 15,651,397 |  |  |  | 0.96 |  |  |  | 25,797,283 |  |  |  | 1.20 |
Issued |  |  | 4,419,620 |  |  |  | 0.35 |  |  |  | 21,731,011 |  |  |  | 0.09 |  |  |  | 3,984,731 |  |  |  | 0.25 |
Exercised |  |  | (12,580,314 | ) |  |  | 0.13 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cancelled / expired |  |  | (1,472,223 | ) |  |  | 0.25 |  |  |  | (11,666,666 | ) |  |  | 1.20 |  |  |  | (14,130,617 | ) |  |  | 1.20 |
Outstanding, end of year |  |  | 16,082,825 |  |  |  | 0.15 |  |  |  | 25,715,742 |  |  |  | 0.11 |  |  |  | 15,651,397 |  |  |  | 0.96 |
Notes to the Consolidated Financial Statements For the year ended December 31, 2021 (Expressed in Canadian dollars) At December 31, 2021, the Company had outstanding common share purchase warrants exercisable to acquire common shares of the Company as follows: SCHEDULE OF NUMBER AND WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OUTSTANDING WARRANTS
Warrants Outstanding |  |  | Expiry Date |  | Exercise Price ($) |  |  | Weighted Average remaining contractual life (years) |
| 10,871,817 | 1 |  | August 13, 2022 |  |  | 0.09 |  |  |  | 0.41 |
| 1,204,638 | 1 |  | August 31, 2022 |  |  | 0.09 |  |  |  | 0.05 |
| 4,006,370 |  |  | April 16, 2023 |  |  | 0.35 |  |  |  | 0.33 |
| 16,082,825 |  |  |  |  |  |  |  |  |  | 0.79 |
1 | The warrants are subject to an acceleration clause such that if the volume-weighted average trading price of the Company’s common shares on the TSX-V exceeds $0.12 per common share for a period of 10 consecutive trading days at any date before the expiration date of such warrants, the Company may, at its option, accelerate the warrant expiry date to within 30 days. To December 31, 2021, the Company’s common shares have met the criterion for acceleration. The Company, however, has not accelerated the warrant expiry date.
The average share price at the dates the finders’ warrants were exercised was $0.34.
| d) | Stock options
The Company adopted a Stock Option Plan (the “Plan”), providing the authority to grant options to directors, officers, employees and consultants enabling them to acquire up to 10% of the issued and outstanding common stock of the Company. Under the Plan, the exercise price of each option equals the market price or a discounted price of the Company’s stock as calculated on the date of grant. The options can be granted for a maximum term of 10 years. A summary of option activity under the Plan during the years ended December 31, 2021, December 31, 2020 and December 31, 2019 is as follows: SCHEDULE OF NUMBER AND WEIGHTED AVERAGE EXERCISE PRICES OF SHARE OPTIONS
|  | December 31, 2021 |  |  | December 31, 2020 |  |  | December 31, 2019 |
|  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |  |  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |  |  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |
Outstanding, beginning of year |  |  | 7,978,725 |  |  |  | 0.17 |  |  |  | 2,130,550 |  |  |  | 1.51 |  |  |  | 2,594,550 |  |  |  | 1.80 |
Issued |  |  | 8,178,972 |  |  |  | 0.37 |  |  |  | 7,850,000 |  |  |  | 0.15 |  |  |  | - |  |  |  | - |
Exercised |  |  | (500,000 | ) |  |  | 0.22 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cancelled / expired |  |  | (603,100 | ) |  |  | 0.31 |  |  |  | (2,001,825 | ) |  |  | 1.51 |  |  |  | (464,000 | ) |  |  | 4.23 |
Outstanding, end of year |  |  | 15,054,597 |  |  |  | 0.27 |  |  |  | 7,978,725 |  |  |  | 0.17 |  |  |  | 2,130,550 |  |  |  | 1.51 |
During the year ended December 31, 2021, the Company granted an aggregate total of 8,178,972 stock options to employees, directors and consultants with a maximum term of 5 years. All options vest immediately and are exercisable as to 3,185,000 options at $0.32 per share and 4,993,972 options at $0.40 per share. The Company calculates the fair value of all stock options using the Black-Scholes Option Pricing Model. The fair value of options granted during the year ended December 31, 2021 amounted to $2,530,706 and was recorded as a share-based payment expense. The weighted average fair value of options granted during the year ended December 31, 2021 is $0.31 per option. During the year ended December 31, 2020, the Company granted an aggregate total of 7,850,000 stock options to employees, directors and consultants with a maximum term of 5 years. All options vest immediately and are exercisable as to 6,650,000 options at $0.16 per share and 1,200,000 options at $0.09 per share. The Company calculates the fair value of all stock options using the Black-Scholes Option Pricing Model. The fair value of options granted during the year ended December 31, 2020 amounted to $969,391 and was recorded as a share-based payment expense. There were no incentive stock options granted during the year ended December 31, 2019. Notes to the Consolidated Financial Statements For the year ended December 31, 2021 (Expressed in Canadian dollars) The fair value of stock options granted and vested during the years ended December 31, 2021, 2020 and 2019 was calculated using the following assumptions: SCHEDULE OF INPUTS TO OPTION PRICING MODEL
|  | December 31, 2021 |  |  | December 31, 2020 |  |  | December 31, 2019 |
Expected dividend yield |  |  | 0 | % |  |  | 0 | % |  |  | - |
Expected share price volatility |  |  | 126.4% - 127.8 | % |  |  | 121.5% - 125 | % |  |  | - |
Risk free interest rate |  |  | 0.93% - 1.34 | % |  |  | 0.39% - 1.21 | % |  |  | - |
Expected life of options |  |  | 5 years |  |  |  | 5 years |  |  |  | - |
Details of options outstanding as at December 31, 2021 are as follows: SCHEDULE OF NUMBER AND WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OUTSTANDING SHARE OPTIONS
Options Outstanding |  |  | Options Exercisable |  |  | Expiry Date |  | Exercise Price ($) |  |  | Weighted average remaining contractual life (years) |
| 40,625 |  |  |  | 40,625 |  |  | February 21, 2022* |  |  | 1.20 |  |  |  | 0.00 |
| 35,000 |  |  |  | 35,000 |  |  | February 28, 2023 |  |  | 1.20 |  |  |  | 0.00 |
| 5,800,000 |  |  |  | 5,800,000 |  |  | February 24, 2025 |  |  | 0.16 |  |  |  | 1.22 |
| 1,200,000 |  |  |  | 1,200,000 |  |  | August 19, 2025 |  |  | 0.09 |  |  |  | 0.29 |
| 2,985,000 |  |  |  | 2,985,000 |  |  | February 25, 2026 |  |  | 0.32 |  |  |  | 0.83 |
| 4,993,972 |  |  |  | 4,993,972 |  |  | October 25, 2026 |  |  | 0.40 |  |  |  | 1.61 |
| 15,054,597 |  |  |  | 15,054,597 |  |  |  |  |  |  |  |  |  | 3.95 |
* | Subsequently expired, unexercised.
The average share price at the dates the options were exercised was $0.485.
| e) | Reserve
The reserve records items recognized as stock-based compensation expense and other share-based payments until such time that the stock options or warrants are exercised, at which time the corresponding amount will be transferred to share capital. Amounts recorded for forfeited or expired unexercised options and warrants are transferred to deficit. During the year ended December 31, 2021, the Company transferred $203,865 (December 31, 2020 - $3,782,706) (December 31, 2019 - $3,860,656) to deficit for expired options and warrants and $666,478 to share capital for exercised warrants and options (December 31, 2020 and 2019 - $Nil). During the year ended December 31, 2021, the Company recorded $2,530,706 (December 31, 2020 - $969,391) of share-based payments to reserves. There were no share-based payments during the year ended December 31, 2019.

X
- References No definition available. + Details
Name: | WSCRF_DisclosureOfShareCapitalWarrantsAndOptionsAbstract
Namespace Prefix: | WSCRF_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for share capital, reserves and other equity interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 79 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration